Sompo International Introduces Transaction Risk Insurance in Europe
PEMBROKE, Bermuda, June 14, 2018 (GLOBE NEWSWIRE) -- Sompo International Holdings Ltd., a Bermuda-based specialty provider of property and casualty insurance and reinsurance, announced today that the company's European Specialty platform has introduced a new Transaction Risk insurance line of business, expanding its Professional Lines insurance offerings in Europe.
This new business targets parties on either side of a merger or acquisition transaction, providing coverage against losses arising from Warranties and Indemnities (W&I) breaches and other risks. The program targets public and private companies domiciled or conducting their core business throughout Europe. Primary and excess attachments are available for buyer-side W&I, seller-side W&I, seller-induced buyer-side W&I and tax liability insurance for European tax risks related to M&A transactions.
Mr. Thomas Mannsdorfer, Executive Vice President and Head of European Specialty Underwriting at Sompo International, commented, "Since the launch of Sompo International's European platform in March, we've focused on delivering market-leading management liability, professional indemnity, financial institutions and cyber liability products to clients across Europe. Our new M&A products expand these capabilities, further strengthening our ability to help companies manage the broad range of risks associated with their fiduciary and contractual responsibilities."
Mr. Richard Allen, Executive Vice President, Head of Professional Lines, London Market & Europe Insurance, added, "Backed by Sompo International's A+ rated underwriting capacity and with the flexibility to service accounts through both our London based and new European entities, the introduction of these additional professional lines products complement our growing portfolio. Thomas' in-depth knowledge in this area along with new underwriting talent recruited to our European Specialty team will enhance Sompo International's presence in this important market."
About Sompo International
Sompo International Holdings, Ltd. is a global specialty provider of property and casualty insurance and reinsurance, headquartered in Bermuda. Through its operating subsidiaries, Sompo International writes agriculture, professional lines, property, marine and energy, and casualty and other specialty lines of insurance and catastrophe, property, casualty, professional lines, weather risk and specialty lines of reinsurance. Sompo International companies are wholly owned subsidiaries of Sompo Holdings, Inc., whose core business encompasses one of the largest property and casualty insurance groups in the Japanese domestic market. We maintain excellent financial strength as evidenced by the ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard and Poor's on our principal operating subsidiaries. Sompo International's headquarters are located at Waterloo House, 100 Pitts Bay Road, Pembroke HM 08, Bermuda and its mailing address is Sompo International, Suite No. 784, No. 48 Par-la-Ville Road, Hamilton HM 11, Bermuda. For more information about Sompo International, please visit www.sompo-intl.com.
Phone: +1 441 278 0988
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sompo International via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Incap’s Board of Directors resolved on a share-based incentive scheme for the company’s CEO26.5.2020 15:20:00 CEST | Press release
Incap Corporation Stock Exchange Release 26 May 2020 at 4.20 p.m. (EEST) Incap’s Board of Directors resolved on a share-based incentive scheme for the company’s CEO Incap Corporation’s Board of Directors has resolved to implement a long-term share-based incentive scheme for the company’s CEO, Otto Pukk. The incentive scheme’s purpose is to support Incap’s strategy and incentivize the CEO in the effective implementation of the post-acquisition integration of AWS Electronics Group. The company has not previously had a share-based incentive scheme for CEO Otto Pukk. Any reward payable based on the incentive scheme is paid out entirely as Incap’s new shares. The earnings period for the CEO’s incentive scheme includes the ongoing and next financial period of the company so that it will end on 31 December 2021. During the earnings period, the CEO may earn a performance-based reward amounting up to 5,730 new shares of the company based on the development of the company’s EBIT provided that th
USD TENDER OPERATION ANNOUNCEMENT26.5.2020 15:00:00 CEST | Press release
USD TENDER OPERATION ANNOUNCEMENT MAY-28-2020 Transaction type: Reverse TransactionOperation type:Liquidity providingTender date:MAY-28-2020Time for submission of bids14.00-14.30 (CEST)Start date:JUN-1-2020Maturity date:AUG-24-2020Duration:84 daysOffered volume:10.0 bln Min bid amount: 100 mlnMaximum bid amount: 4.0 blnMax number of bids:10Lowest interest supplement:0.25 percentage pointsMin bid rate:t.b.a.Allocation time:15.00 (CEST) on Tender date Approved counterparties are invited to submit bids to the Riksbank, tel +46 8 6966970 by 14.30 (CEST) pm on May 28, 2020. Confirmation of bids to e-mail: https://www.globenewswire.com/Tracker?data=m3O1JLVEmyGluQh0AvJvGpAt6AU1L2Qmmo7-ktvXU5fV3d13DU2X3whKS1qawLrAoNyGIVGKywGQ1AWND3wnpA== firstname.lastname@example.org
Corline Biomedical AB presenterar på Redeyes Growth Day 202026.5.2020 13:54:48 CEST | Pressemelding
Den 2 juni kl 14.00 presenterar Henrik Nittmar, VD i Corline Biomedical AB den senaste utvecklingen i bolaget på Redeye. Presentationen livesänds och kan följas på https://www.redeye.se/live/growth-day-2020 där presentationen även i efterhand kommer finnas tillgänglig, samt på vår bolagssida i Redeye Universe https://www.redeye.se/company/corline-biomedical. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: email@example.com Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: firstname.lastname@example.org Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administrati
Corline Biomedical AB presenterar på Redeyes Temaevent Orphan Drugs26.5.2020 13:49:07 CEST | Pressemelding
Corline Biomedical AB (”Corline”) kommer att presentera sin verksamhet på Redeyes temaevent Orphan Drugs. Presentationen sker kl 11:30 den 27 maj 2020 i Stockholm och livesänds via Redeyes hemsida. Konferensprogrammet och livesändningen görs tillgängliga via Redeyes hemsida https://www.redeye.se/live/orphan-27-maj. För mer information, vänligen kontakta Henrik Nittmar, VD Telefon: 018-71 30 90 E-post: email@example.com Certified Adviser Svensk Kapitalmarknadsgranskning Telefon: 011-32 30 732 E-post: firstname.lastname@example.org Corline Biomedical AB arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget planerar kliniska studier inom diabetes typ 1 och njurtransplantation, för vilket Corline även har erhållit särläkemedelsstatus (”Orphan Drug”). Inom ramen för helägda dotterbolaget Corline Pharma AB utvärderas in vivo-administration av Corlines heparinsubstans och sedan tidigare
Lundin Gold Inc. Announces C$50 Million Bought Deal Financing26.5.2020 13:30:02 CEST | Press release
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, May 26, 2020 (GLOBE NEWSWIRE) -- Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) has announced today that it has entered into an agreement with BMO Capital Markets (“BMO”), under which BMO has agreed to buy on a bought deal basis 4,150,000 common shares (the “Common Shares”), at a price of C$12.05 per Common Share for gross proceeds of approximately C$50 million (the “Offering”). The Company has granted BMO an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any. The offering is expected to close on or about June 11, 2020 and is subject to Lundin Gold receiving all necessary regulatory approvals. Newcrest Mining Limited, which currently holds approximately 32% of the Company’s issued and outsta
PCI Biotech: Disclosure of voting rights for Chairman of the Board26.5.2020 13:20:03 CEST | Press release
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 27 May 2020. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,171,710 additional shares. In total, Mr. Bøhn will represent and vote for 19.6 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 27 May 2020. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO, email@example.com, Mobile: +47 9400 5757